No Data
FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Express News | Compass Pathways PLC in Addition, Selling Security Holders Offering up to 9.45 Mln Ordinary Shares - SEC Filing
Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
RBC Capital analyst Leonid Timashev maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 44.3%
RBC Capital Remains a Buy on COMPASS Pathways (CMPS)